The University of Queensland has been selected as one of the first launch institutions in the world to partner with biotechnology company Moderna to research and develop vaccines to tackle the world’s greatest global public health threats.
The partnership, brokered by two of the University’s leading researchers Professor Mark Walker and Professor Paul Young, will allow UQ scientists access to Boston-based pharmaceutical company Moderna’s mRNA platform to develop mRNA vaccines for neglected and emerging viruses.
“This partnership is a coup for UQ with advances in vaccine delivery potentially saving thousands of lives in developing countries,” Professor Young said.
“It is also recognition that UQ is a centre of excellence in vaccine research and discovery.”
Professor Young said there were at least 10 disease research projects underway at UQ that could benefit immediately from the mRNA Access partnership.